Gerresheimer (GXI) Given a €55.90 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. set a €55.90 ($65.00) target price on Gerresheimer (ETR:GXI) in a report released on Monday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

Other research analysts also recently issued research reports about the stock. Deutsche Bank set a €83.00 ($96.51) price objective on shares of Gerresheimer and gave the stock a buy rating in a research report on Tuesday, April 2nd. Credit Suisse Group set a €82.00 ($95.35) price objective on shares of Gerresheimer and gave the stock a buy rating in a research report on Friday, April 5th. Berenberg Bank set a €81.00 ($94.19) price objective on shares of Gerresheimer and gave the stock a buy rating in a research report on Thursday, April 11th. Independent Research set a €66.00 ($76.74) price objective on shares of Gerresheimer and gave the stock a neutral rating in a research report on Thursday, February 14th. Finally, DZ Bank reaffirmed a neutral rating on shares of Gerresheimer in a research report on Tuesday, April 2nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of €69.17 ($80.43).

Shares of Gerresheimer stock opened at €68.25 ($79.36) on Monday. The company has a current ratio of 0.74, a quick ratio of 0.51 and a debt-to-equity ratio of 108.42. Gerresheimer has a 52-week low of €51.10 ($59.42) and a 52-week high of €80.25 ($93.31). The company has a market capitalization of $2.14 billion and a PE ratio of 16.62.

Gerresheimer Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

See Also: Why Invest in Dividend Achievers?

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.